#1 Clinical Trials Search in Europe

Emtricitabine

Emtricitabine, a nucleoside reverse transcriptase inhibitor, is being studied in various clinical trials for its effectiveness in treating HIV, hepatitis B, and potentially Alzheimer’s disease. These trials aim to evaluate the drug’s safety, efficacy, and potential new applications across different patient populations, including adults, children, and pregnant women.

Table of Contents

What is Emtricitabine?

Emtricitabine, also known as FTC, is an antiretroviral medication primarily used in the treatment of HIV (Human Immunodeficiency Virus) infections[1]. It belongs to a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). Emtricitabine is often marketed under brand names such as Emtriva or Huierding[2].

Uses of Emtricitabine

Emtricitabine is primarily used for:

  • HIV Treatment: It is a key component in many antiretroviral therapy regimens for treating HIV infections[3].
  • HIV Prevention: It is used as part of pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals[4].
  • Hepatitis B Treatment: Some studies have explored its use in treating chronic hepatitis B infections[2].

How Emtricitabine Works

Emtricitabine works by inhibiting the reverse transcriptase enzyme of HIV and hepatitis B virus. This enzyme is crucial for the viruses to replicate their genetic material. By blocking this process, emtricitabine helps to reduce the amount of virus in the body, which is often referred to as the viral load[1].

Emtricitabine in Combination Therapies

Emtricitabine is rarely used alone. It is typically combined with other antiretroviral drugs to create more effective treatment regimens. Some common combinations include:

  • Truvada: A combination of emtricitabine and tenofovir, used for both HIV treatment and prevention[4].
  • Atripla: A combination of efavirenz, emtricitabine, and tenofovir[5].
  • Eviplera (also known as Complera): A combination of rilpivirine, emtricitabine, and tenofovir[3][5].

Emtricitabine for Different Patient Groups

Research has been conducted on the use of emtricitabine in various patient populations:

  • Pediatric Patients: Studies have explored the safety and efficacy of emtricitabine in HIV-infected children and adolescents[1].
  • Pregnant Women: Research has been conducted on the use of emtricitabine in pregnant women with chronic hepatitis B to prevent mother-to-child transmission[6].
  • Adults with HIV and Hepatitis B Co-infection: Some studies have investigated the use of emtricitabine in patients with both HIV and hepatitis B[7].

Potential Side Effects

Like all medications, emtricitabine can cause side effects. Common side effects may include:

  • Headache
  • Diarrhea
  • Nausea
  • Rash
  • Fatigue

More serious side effects can occur but are less common. It’s important to discuss potential side effects with your healthcare provider[4].

Ongoing Research

Researchers continue to study emtricitabine for potential new uses and to better understand its long-term effects. Some areas of ongoing research include:

  • Lipid Profile Changes: Studies are investigating how switching between different emtricitabine-containing regimens might affect patients’ lipid profiles (the levels of different fats in the blood)[5].
  • Alzheimer’s Disease: Interestingly, some researchers are exploring whether emtricitabine might have potential in treating Alzheimer’s disease, based on its anti-inflammatory properties[8].
Aspect Details
Conditions Studied HIV-1 infection, Chronic Hepatitis B, Alzheimer’s disease
Patient Populations Adults, children, pregnant women
Dosage Forms Oral capsules, oral solution
Common Dosages 200 mg daily for adults, 6 mg/kg for children (max 200-240 mg)
Combination Therapies Often combined with other antiretrovirals (e.g., tenofovir, efavirenz, rilpivirine)
Primary Outcomes Viral suppression, safety and tolerability, prevention of vertical transmission
Secondary Outcomes Changes in CD4+ counts, ALT normalization, HBeAg loss/seroconversion, cognitive function changes
Safety Monitoring Adverse events, laboratory toxicities, birth defects in newborns of treated mothers
Novel Applications Potential use in Alzheimer’s disease treatment
Study Durations Vary from 48 weeks to 96 weeks, with some extending to post-delivery follow-ups

FAQ

  • What conditions is emtricitabine being studied for in clinical trials? Emtricitabine is being studied for HIV-1 infections, chronic hepatitis B, and potentially Alzheimer's disease. It is being tested in various patient groups, including adults, children, and pregnant women.
  • How is emtricitabine being used in HIV treatment trials? In HIV treatment trials, emtricitabine is often used in combination with other antiretroviral drugs. For example, it's being studied as part of combination therapies like Atripla (efavirenz + emtricitabine + tenofovir) and Eviplera (rilpivirine + emtricitabine + tenofovir) to assess their effects on viral suppression and lipid profiles in HIV-1 patients.
  • What are researchers studying about emtricitabine in hepatitis B trials? In hepatitis B trials, researchers are evaluating emtricitabine's effectiveness in reducing viral load (HBV DNA levels), improving liver function (ALT normalization), and preventing vertical transmission from pregnant women to their newborns. They're also assessing its safety profile and potential for developing drug resistance.
  • How is emtricitabine being investigated for Alzheimer's disease? A clinical trial is exploring the potential of emtricitabine in treating Alzheimer's disease. The study aims to assess its safety and tolerability in patients with mild cognitive impairment or early Alzheimer's disease, and to evaluate its effects on inflammatory biomarkers and cognitive function measures.
  • What are some common outcomes being measured in emtricitabine clinical trials? Common outcomes measured in emtricitabine trials include viral suppression (HIV or HBV DNA levels), changes in CD4+ cell counts for HIV patients, liver function tests for hepatitis B patients, safety and tolerability assessments, and in some cases, cognitive function tests for Alzheimer's disease research. Researchers also monitor for potential side effects and drug resistance.

Ongoing Clinical Trials on Emtricitabine

  • Study of MK-8527 taken once monthly compared to emtricitabine/tenofovir taken daily for HIV-1 prevention

    Not recruiting

    3 1 1
    Investigated drugs:
    France

  • Study on Lenacapavir for HIV Prevention in Individuals at Risk of HIV Infection

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Emtricitabine and Tenofovir Alafenamide for HIV-1 Prevention in Men and Transgender Women at Risk

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany Ireland Italy +1

  • Study of Weekly Oral GS-1720 and GS-4182 for Untreated HIV-1 Patients

    Not recruiting

    4 1 1 1
    Investigated drugs:
    Germany Poland Portugal Romania Spain

  • Study on HIV Treatment Interruption in Children with Perinatal HIV Using Lamivudine and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Dolutegravir and Lamivudine for Maintaining Viral Control in Children with HIV Aged 2 to Under 15 Years

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany The Netherlands Poland Spain

  • Study to Compare Weekly Islatravir/Lenacapavir with Bictegravir/Emtricitabine/Tenofovir in People with HIV-1 Who Are Virologically Suppressed

    Not recruiting

    3 1 1
    Investigated drugs:
    France Germany Spain

  • Study on the Effects of Ianalumab with Standard Therapy for Patients with Active Lupus Nephritis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Estonia France Germany Hungary Italy +3

  • Study Comparing DTG/3TC and BIC/FTC/TAF for Maintaining HIV Control in Adults

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Emtricitabine: A nucleoside reverse transcriptase inhibitor used in the treatment of HIV and hepatitis B infections. It works by inhibiting viral replication.
  • Viral suppression: The reduction of virus levels in the body to very low or undetectable levels, often measured by HIV RNA or HBV DNA levels in the blood.
  • HBeAg: Hepatitis B e-antigen, a protein produced by the hepatitis B virus. Its presence in the blood indicates active viral replication.
  • ALT normalization: The return of alanine aminotransferase (ALT) levels to the normal range. ALT is an enzyme that can indicate liver damage when elevated.
  • Vertical transmission: The passage of a disease-causing agent from mother to baby during pregnancy, childbirth, or breastfeeding.
  • Lipidomic profile: A comprehensive analysis of lipid molecules in biological samples, used to study the effects of drugs on lipid metabolism.
  • Mild Cognitive Impairment (MCI): A condition characterized by a slight but noticeable decline in cognitive abilities, often considered an early stage of dementia.
  • CD4+ cell count: A measure of the number of T helper cells in the blood, used to assess the strength of the immune system in HIV patients.
  • Antiretroviral therapy: A combination of medications used to treat HIV infection by suppressing viral replication and slowing the progression of the disease.
  • HBsAg: Hepatitis B surface antigen, a protein on the surface of the hepatitis B virus. Its presence in the blood indicates a current hepatitis B infection.

References

  1. https://clinicaltrials.gov/study/NCT00642291
  2. https://clinicaltrials.gov/study/NCT02327663
  3. https://clinicaltrials.gov/study/NCT02104700
  4. https://clinicaltrials.gov/study/NCT02968576
  5. https://clinicaltrials.gov/study/NCT02547844
  6. https://clinicaltrials.gov/study/NCT02327702
  7. https://clinicaltrials.gov/study/NCT00391638
  8. https://clinicaltrials.gov/study/NCT04500847